PGDx elio plasma focus Dx
FDA-authorized plasma cfDNA next-generation sequencing tumor-profiling test for patients already diagnosed with solid malignant neoplasms.
- Developer
- PGDx
- Intended use
- Other
- Cancer scope
- Not reported
- Specimen
- Peripheral whole blood
- Molecular modality
- DNA mutation
- Current version
- PGDx elio plasma focus Dx DEN230046
- Evidence context
- 0 structured studies · 0 indexed performance results · 1 sources
Why can reported performance numbers differ? MDI keeps each result attached to its study, population, stage or stratum, test version and source rather than treating performance as a fixed property of the test.